Modality
Bispecific Ab
MOA
JAK1i
Target
FcRn
Pathway
STING
LN
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
~Jan 2017
→ ~Apr 2018
Phase 3
~Jul 2018
→ ~Oct 2019
NDA/BLA
Jan 2020
→ Nov 2030
NDA/BLACurrent
NCT07186606
2,365 pts·LN
2020-02→2028-09·Completed
NCT08377053
736 pts·LN
2020-01→2030-11·Not yet recruiting
3,101 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-09-262.5y awayPh3 Readout· LN
2030-11-124.6y awayPh3 Readout· LN
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Not yet…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2028-09-26 · 2.5y away
LN
Ph3 Readout
2030-11-12 · 4.6y away
LN
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07186606 | NDA/BLA | LN | Completed | 2365 | PANSS |
| NCT08377053 | NDA/BLA | LN | Not yet recr... | 736 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ITC-879 | Intra-Cellular | Approved | FcRn |